A new study published in The Lancet reported that Boehringer Ingelheim’s BI 695501 (biosimilar adalimumab) has similar safety and efficacy to reference adalimumab in patients with Crohn’s disease.
Pearce IP’s Adele Chadwick and Chris Vindurampulle Honoured in WIPR Diversity’s Top 100 2024
We are proud to announce that two of Pearce IP’s Leaders have been honoured by WIPR Diversity Top 100 2024: Adele Chadwick, Pearce IP’s Executive,...